公开(公告)号：US20240018120A1

公开(公告)日：2024-01-18

申请号：US18252611

申请日：2021-11-12

Applicant: H. LUNDBECK A/S

Inventor： John J.M. WIENER ,  Cheryl A. GRICE ,  Daniel J. BUZARD ,  Justin S. CISAR ,  Olivia Delene WEBER ,  Amy ALLAN ,  Nicholas RAFFAELE ,  Jeanne V. MOODY ,  Michael B. SHAGHAFI

IPC: C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D401/14 ,  C07D487/04 ,  C07D471/04 ,  C07D221/20 ,  C07D417/12 ,  A61P29/00 ,  A61P25/08

CPC classification number: C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D401/14 ,  C07D487/04 ,  C07D471/04 ,  C07D221/20 ,  C07D417/12 ,  A61P29/00 ,  A61P25/08

Abstract: Provided herein are substituted 1,1,1,3,3,3-hexafluoropropan-2-yl 6-azaspiro[2.5]octane-6-carboxylate compounds and pharmaceutical compositions comprising said compounds. The compounds and compositions provided herein are useful as inhibitors of MAGL. Furthermore, the compounds and compositions as provided herein are useful for the treatment of diseases and disorders benefiting from the inhibition of MAGL.

公开(公告)号：US20230357190A1

公开(公告)日：2023-11-09

申请号：US18311759

申请日：2023-05-03

Applicant: H. LUNDBECK A/S

Inventor： Thomas VETTER ,  John J.M. WIENER ,  Cheryl A. GRICE ,  Daniel J. BUZARD ,  Justin S. CISAR ,  Olivia Delene WEBER ,  Amy ALLAN ,  Nicholas RAFFAELE ,  Jeanne V. MOODY ,  Michael B. SHAGHAFI

IPC: C07D401/12

CPC classification number: C07D401/12 ,  C07B2200/13

Abstract: Described herein is new crystalline forms of the MAGL inhibitor 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate.

公开(公告)号：US20220153721A1

公开(公告)日：2022-05-19

申请号：US17524632

申请日：2021-11-11

Applicant: H. LUNDBECK A/S

Inventor： John J.M. WIENER ,  Cheryl A. GRICE ,  Daniel J. BUZARD ,  Justin S. CISAR ,  Olivia Delene WEBER ,  Amy ALLAN ,  Nicholas RAFFAELE ,  Jeanne MOODY ,  Michael B. SHAGHAFI

IPC: C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07F9/6558 ,  C07D401/14 ,  C07D221/20 ,  C07D487/04 ,  C07D471/04 ,  C07D417/12 ,  A61P25/08 ,  A61P25/04

Abstract: Provided herein are substituted 1,1,1,3,3,3-hexafluoropropan-2-yl 6-azaspiro[2.5]octane-6-carboxylate compounds and pharmaceutical compositions comprising said compounds. The compounds and compositions provided herein are useful as inhibitors of MAGL. Furthermore, the compounds and compositions as provided herein are useful for the treatment of diseases and disorders benefiting from the inhibition of MAGL.